Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth Garrett-Mayer

Showing results (131-140 of 289) with videos related to

Pageof 29
Sort By:
Journal of Oncology Practice|June 16, 2018
The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census SurveyM Kelsey Kirkwood, Amy Hanley, Suanna S Bruinooge, et al.
JCO Global Oncology|September 19, 2025
Understanding Barriers to Clinical Cancer Research in the Asia-PacificRashid N Lui, Jimmy Billod, Sophia Frentzas, et al.
Journal of Geriatric Oncology|February 24, 2021
Challenges and opportunities to developing a frailty index using electronic health record dataLaura A Levit, Melinda W Kaltenbaugh, Allison Magnuson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lungJyoti Mehrotra, Mustafa Vali, Megan McVeigh, et al.
Urology|March 27, 2007
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapyGopal K Bajaj, Zhe Zhang, Elizabeth Garrett-Mayer, et al.
American Journal of Clinical Oncology|October 21, 2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancerBree N Ruppert, John M Watkins, Keisuke Shirai, et al.
Japanese Journal of Radiology|June 30, 2010
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomesJohn M Watkins, John A Fortney, Amy E Wahlquist, et al.
Journal for Immunotherapy of Cancer|March 22, 2025
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapyThomas U Marron, Jason J Luke, Brianna Hoffner, et al.
Journal of Medical Imaging and Radiation Oncology|October 21, 2010
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survivalJohn M Watkins, Amy E Wahlquist, A Jason Zauls, et al.
Neoplasia (New York, N.Y.)|September 7, 2012
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancerColin D Weekes, Dongweon Song, John Arcaroli, et al.
Pageof 29

Showing results (131-140 of 289) with videos related to

Sort By:
Pageof 29
Journal of Oncology Practice|June 16, 2018
The State of Oncology Practice in America, 2018: Results of the ASCO Practice Census SurveyM Kelsey Kirkwood, Amy Hanley, Suanna S Bruinooge, et al.
JCO Global Oncology|September 19, 2025
Understanding Barriers to Clinical Cancer Research in the Asia-PacificRashid N Lui, Jimmy Billod, Sophia Frentzas, et al.
Journal of Geriatric Oncology|February 24, 2021
Challenges and opportunities to developing a frailty index using electronic health record dataLaura A Levit, Melinda W Kaltenbaugh, Allison Magnuson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2004
Very high frequency of hypermethylated genes in breast cancer metastasis to the bone, brain, and lungJyoti Mehrotra, Mustafa Vali, Megan McVeigh, et al.
Urology|March 27, 2007
Phase II study of imatinib mesylate in patients with prostate cancer with evidence of biochemical relapse after definitive radical retropubic prostatectomy or radiotherapyGopal K Bajaj, Zhe Zhang, Elizabeth Garrett-Mayer, et al.
American Journal of Clinical Oncology|October 21, 2009
Cisplatin/Irinotecan versus carboplatin/paclitaxel as definitive chemoradiotherapy for locoregionally advanced esophageal cancerBree N Ruppert, John M Watkins, Keisuke Shirai, et al.
Japanese Journal of Radiology|June 30, 2010
Once-daily radiotherapy to > or =59.4 Gy versus twice-daily radiotherapy to > or =45.0 Gy with concurrent chemotherapy for limited-stage small-cell lung cancer: a comparative analysis of toxicities and outcomesJohn M Watkins, John A Fortney, Amy E Wahlquist, et al.
Journal for Immunotherapy of Cancer|March 22, 2025
A SITC vision: adapting clinical trials to accelerate drug development in cancer immunotherapyThomas U Marron, Jason J Luke, Brianna Hoffner, et al.
Journal of Medical Imaging and Radiation Oncology|October 21, 2010
Involved-field radiotherapy with concurrent chemotherapy for limited-stage small-cell lung cancer: disease control, patterns of failure and survivalJohn M Watkins, Amy E Wahlquist, A Jason Zauls, et al.
Neoplasia (New York, N.Y.)|September 7, 2012
Stromal cell-derived factor 1α mediates resistance to mTOR-directed therapy in pancreatic cancerColin D Weekes, Dongweon Song, John Arcaroli, et al.
Pageof 29